Latest news with #GodavariBiorefineries
Business Standard
07-07-2025
- Health
- Business Standard
Godavari Biorefineries' anti-cancer patent now validated in Spain and the UK
And as Unitary Patent covering multiple EU member states Godavari Biorefineries announced that its European patent for a novel anti-cancer molecule has been validated in Spain, the United Kingdom, and as a Unitary Patent covering multiple EU member states. This milestone underscores the company's growing presence in high-impact scientific innovation, led by its dedicated Anti-Cancer Research Segment. The patented molecule has demonstrated efficacy against both cancer cells and cancer stem cells, marking a promising advance toward more targeted and effective cancer therapies. It has shown potential in the treatment of various cancers, including breast and prostate cancer, with encouraging efficacy and safety profiles in preclinical animal studies. The molecule is currently in Phase 1a clinical trials to assess safety in human patients with advanced solid tumors as well as in healthy volunteers.
&w=3840&q=100)
Business Standard
04-07-2025
- Business
- Business Standard
Godavari Biorefineries share price hits 5% upper circuit today; here's why
Godavari Biorefineries share price: Godavari Biorefineries share price was in demand on Friday, July 4, 2025, with the scrip hitting 5 per cent upper circuit at ₹258.60 per share. However, at 10:20 AM, Godavari Biorefineries share price was off highs, but continued to trade higher, up 1.60 per cent at ₹250.25 per share. In comparison, BSE Sensex was trading flat at 83,229.22 levels. Why did Godavari Biorefineries hit 5% upper circuit today? Godavari Biorefineries share price rose after the company announced that it has been granted a patent in Europe for its novel anticancer molecule. In an exchange filing, Godavari Biorefineries said, 'This is to inform you that the Company has been granted a patent in Europe for our novel anticancer molecule. This patent is now validated in Spain, the UK, and as a Unitary Patent.' The patent subject area is 'Anti-Cancer Research Segment.' The patent covers a very potent anticancer compound with proven efficacy on cancer and cancer stem cells, the company said. Godavari Biorefineries Q4 results Godavari Biorefineries reported its financial results for Q4 FY25, showcasing operational resilience despite a slight dip in revenue. The company posted consolidated revenue from operations of ₹579.5 crore, down from ₹615.2 crore in the same quarter last year. However, profitability remained robust, with Ebitda at ₹121.7 crore and a healthy margin of 21 per cent, marginally up from the 20.2 per cent Ebitda margin recorded in Q4FY24. Profit after tax (PAT) stood at ₹71.9 crore, reflecting a PAT margin of 12.4 per cent, higher than the 10.6 per cent in the previous year. On Q4 show, Samir Somaiya, CMD of Godavari Refineries said, 'FY25 was a defining year for Godavari Biorefineries, showcasing our agility, disciplined execution, and strategic progress. Our Bio-based Chemicals segment delivered over 2x growth in Ebitda, propelled by our shift toward high-value, sustainable solutions and enhanced operational efficiencies. We also achieved a record cane crushing of 24.65 lakh tonnes for sugar season 2024-25 at our Sameerwadi restoration of the ethanol blending programme using sugarcane juice enabled us to better utilise our ethanol capacity during the crushing season.' Somaiya added, 'Looking ahead, our 200 KLPD grain/maize distillery is progressing as planned and is expected to be commissioned in Q4 FY26. We are also exploring multi-feedstock options for greater flexibility, while undertaking debottlenecking and expansion initiatives focused on specialty products. FY25 has laid a solid foundation for future growth, and we remain committed to delivering value through innovation, sustainability, and disciplined growth.' About Godavari Biorefineries Godavari Biorefineries Ltd. is one of India's leading producers of ethanol and a pioneer in the manufacturing of ethanol-based chemicals. The company boasts a diversified product portfolio that includes bio-based chemicals, sugar, rectified spirits, ethanol, various grades of alcohol, and power. Notably, it is the only company in India with such an extensive range of bio-based products, including MPO, natural 1,3-butylene glycol, ethyl vinyl ether, and several other specialty chemicals.
Business Upturn
04-07-2025
- Business
- Business Upturn
Godavari Biorefineries share hits 5% upper circuit on Europe patent win for novel anti-cancer molecule
By Aman Shukla Published on July 4, 2025, 09:31 IST Shares of Godavari Biorefineries surged 5% and hit the upper circuit on July 4, following a key announcement regarding a major breakthrough in its anti-cancer research efforts. In a regulatory filing to the NSE and BSE, the company revealed that it has been granted a European patent for its novel anti-cancer molecule, which has demonstrated high potency against both cancer cells and cancer stem cells. This compound is now officially validated in Spain, the UK, and as a Unitary Patent across Europe. The development falls under the company's 'Anti-Cancer Research Segment', highlighting its focus on cutting-edge oncology innovation. According to the company, this patent not only strengthens its intellectual property portfolio but also reinforces its commitment to developing next-generation cancer therapies. Investors responded positively to the news, sending the stock to its daily upper limit. The development is seen as a significant milestone, potentially opening doors for future collaborations, licensing deals, and expansion into global pharmaceutical markets. This is part of Godavari Biorefineries' broader strategy to diversify into high-value bio-based research areas, beyond its traditional ethanol and bio-chemicals business. Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information. Ahmedabad Plane Crash Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
Business Standard
26-05-2025
- Business
- Business Standard
Godavari Biorefineries hits the roof after Q4 PAT rises 10% YoY to Rs 72 cr
Godavari Biorefineries hit an upper circuit of 20% at Rs 227.80 after the company's consolidated net profit rallied 10.37% to Rs 71.93 for the quarter ended 31 March 2025, compared to Rs 65.17 crore in the corresponding period last year. The growth in profit came despite a 5.80% year-on-year decline in revenue from operations, which stood at Rs 579.50 crore during the quarter. Profit before tax (PBT) surged 5.23% to Rs 95.74 crore from Rs 90.98 crore in the year-ago quarter. EBITDA for the quarter declined marginally by 2.17% to Rs 121.7 crore as against Rs 124.4 crore in Q4 FY24. However, the EBITDA margin improved to 21%, up from 20.2% in the same period last year, aided by better product mix and cost optimization. On the segmental front, revenue from the sugar segment rose 7.52% YoY to Rs 561.50 crore. The biobased chemicals segment posted revenue of Rs 139.13 crore, up 8% YoY, while the distillery segment reported a robust 37.3% YoY growth in revenue to Rs 249.54 crore during the quarter. On a full-year basis, the company's net loss was reported at Rs 23.41 crore in the year ended March 2025, as against a net profit of Rs 12.30 crore during the previous year ended March 2024. Revenue from operations rose 10.88% to Rs 1870.25 crore in the year ended March 2025 as against Rs 1686.67 crore during the previous year ended March 2024. Commenting on the results, Samir Somaiya, CMD, said, FY25 was a defining year for Godavari Biorefineries, showcasing our agility, disciplined execution, and strategic progress. Our bio-based chemicals segment delivered over 2x growth in EBITDA, propelled by our shift toward high-value, sustainable solutions and enhanced operational efficiencies. Looking ahead, our 200 KLPD grain/maize distillery is progressing as planned and is expected to be commissioned in Q4 FY26. We are also exploring multi-feedstock options for greater flexibility while undertaking debottlenecking and expansion initiatives focused on specialty products. FY25 has laid a solid foundation for future growth, and we remain committed to delivering value through innovation, sustainability, and disciplined growth. Godavari Biorefineries is a manufacturer of bio-based chemicals and ethanol.
Business Standard
26-05-2025
- Business
- Business Standard
Godavari Biorefineries consolidated net profit rises 10.37% in the March 2025 quarter
Sales decline 5.80% to Rs 579.50 crore Net profit of Godavari Biorefineries rose 10.37% to Rs 71.93 crore in the quarter ended March 2025 as against Rs 65.17 crore during the previous quarter ended March 2024. Sales declined 5.80% to Rs 579.50 crore in the quarter ended March 2025 as against Rs 615.19 crore during the previous quarter ended March 2024. For the full year,net loss reported to Rs 23.41 crore in the year ended March 2025 as against net profit of Rs 12.30 crore during the previous year ended March 2024. Sales rose 10.88% to Rs 1870.25 crore in the year ended March 2025 as against Rs 1686.67 crore during the previous year ended March 2024. Particulars Quarter Ended Year Ended Mar. 2025 Mar. 2024 % Var. Mar. 2025 Mar. 2024 % Var. Sales 579.50615.19 -6 1870.251686.67 11 OPM % 19.4018.50 - 5.547.92 - PBDT 108.58104.87 4 48.5272.37 -33 PBT 95.7490.98 5 -1.5412.45 PL NP 71.9365.17 10 -23.4112.30 PL
